Mad Money with Jim Cramer - MAD CAP RECAP - The Official Mad Money Blog
RSS FEED
RECENT POSTS
- Lightning Round: Akorn, UnitedHealth, Stillwater Mining and More
- Herbalife Shares Gain on Obesity Play
- Allscripts CEO Talks High Tech Turnaround
- High Gas Price Hasn't Impacted Stock Market
- Waste Management CEO Talks to Cramer
- Lightning Round: R.R. Donnelley & Sons, Hanesbrands, Regeneron Pharmaceuticals and More
- Cramer: Charting Apple
- Cramer's One-on-One With EOG Resources CEO
- Cramer on Why Dow 13,000 Matters
- How to Time Your Sells
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Cramer Slaps a ‘Buy’ on Biogen
Text Size 
Producer
All this week, Cramer has been highlighting drug companies that could have a breakout year and on Thursday, he looked at Biogen.
The biotechnology firm [BIIB
Loading...
()
] not only has a number of popular products on the market, the “Mad Money” host noted, it has an excellent pipeline of drugs in development, too. It’s main focus is on treating multiple sclerosis, which is a chronic disease that attacks the central nervous system. There is no cure, but there are a bunch of drugs that aim to prevent relapses and keep the disease in remission.
Biogen currently has two MS treatments on the market, accounting for 60 percent of its total business. More importantly, though, it’s developing a new orally-delivered therapy that could be the most effective treatment yet. Cramer thinks it could make Biogen a fortune. It’s called BG-12 and given it receives FDA approval, it could go to market by the end of the year. The drug could help Biogen rake in $1.5 billion in sales in 2015, which would be impressive given its total revenues in 2011 was $5 billion.
The stock is currently near its highs, but Cramer still thinks it’s a buy because the future looks bright for this biotech company.
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes
